Finally, plasma samples from SSc patients induced de novo neutrophil activation through an FPR1-dependent mechanism suggesting FPR1 as a potential novel therapeutic target in these patients to reduce neutrophil-mediated inflammation. The gene discussed is FPR1; the disease is systemic sclerosis.